Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Study on the Mode and Mechanism of Ultra-low Frequency rTMS for Sleep Disorders in Patients With Parkinson's Disease

20 marzo 2021 aggiornato da: Lili Cao, Qianfoshan Hospital

Study on the Mode and Mechanism of Ultra-low Frequency Repetitive Transcranial Magnetic Stimulation for Sleep Disorders in Patients With Parkinson's Disease

The study by giving a sleep disorder Parkinson's disease patients with different patterns of ultra-low frequency transcranial magnetic stimulation or sham stimulation, scale for assessment of the patients were observed, hematology and imaging changes before and after therapy, clear ultra-low frequency transcranial magnetic stimulation for sleep disorder Parkinson's disease treatment, to explore the mechanism of action, compare the difference between different modes.

Panoramica dello studio

Descrizione dettagliata

Parkinson's disease is the second most common chronic neurodegenerative disease.At present, researchers focus not only on the motor symptoms of Parkinson's disease, but also on the non-motor symptoms of Parkinson's disease (including mood disorders, sleep disorders, cognitive decline, and autonomic nervous kinetic disorder, etc.).The principle of transcranial magnetic stimulation is based on the electromagnetic principle proposed by Faraday. When an electrifying coil is suspended over the scalp at a certain distance, the magnetic field generated by the coil current and the electric field generated by the magnetic field can reach the skull and directly or indirectly affect the synapses and neurons in the brain.The study by giving a sleep disorder Parkinson's disease patients with different patterns of ultra-low frequency transcranial magnetic stimulation or sham stimulation, scale for assessment of the patients were observed, hematology and imaging changes before and after therapy, clear ultra-low frequency transcranial magnetic stimulation for sleep disorder Parkinson's disease treatment, to explore the mechanism of action, compare the difference between different modes.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

99

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Shandong
      • Jinan, Shandong, Cina
        • The First Affiliated Hospital Of Shandong First Medical University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • in line with international Movement disorders association (the Movement Disorder Society, MDS) in 2015 the diagnosis of Parkinson's disease diagnosis standard and China standard (2016)
  • can cooperate to complete rating scale, the sleep monitoring, imaging and blood test
  • have a sleep disorder
  • aged 18 to 70 years old
  • agree to participate in this experiment, and have signed the informed consent

Exclusion Criteria:

  • superposition of diagnosed with Parkinson's syndrome
  • secondary diagnosed Parkinson's syndrome
  • is equipped with heart pacemakers and other metal implants
  • cannot achieve scale assessment
  • has significant malignant diseases
  • has a history of seizures

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation
The study used 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS.
Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
Comparatore attivo: GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation
The study used GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS
Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
Comparatore fittizio: the control group
The instrument is not working, only in exhaust mode.
Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
change from length of sleep at one week
Lasso di tempo: one week
Sleep duration was monitored by polysomnography.It's measured in minutes.
one week
change from ratio of stage 3 sleep in total sleep at one week
Lasso di tempo: one week
The proportion of phase 3 sleep in total sleep was monitored by polysomnography.It's in percentages.
one week
change from limb movement of sleep at one week
Lasso di tempo: one week
The number of body movements during sleep was recorded by polysomnography.It's in units of times per night.
one week
change from nocturnal arousal frequency at one week
Lasso di tempo: one week
The number of nocturnal awakenings was recorded by polysomnography.It's in units of times per night.
one week
change from Pittsburgh sleep quality index scale at one week
Lasso di tempo: 1 day before treatment、1 day after treatment、1 week after treatment、1 moth after treatment
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 2L, and the higher the score, the worse the sleep quality.
1 day before treatment、1 day after treatment、1 week after treatment、1 moth after treatment
Interleukin 6
Lasso di tempo: 1 day before treatment and 1 day after treatment
It plays an important role in central nervous system diseases. In PD, the increase of IL-6 is the body's self-defense mechanism to protect neurons, and the change of IL-6 in peripheral blood can reflect the change of injury aggravation and recovery.It is also associated with psychiatric symptoms, and IL-6 is elevated in major depression.
1 day before treatment and 1 day after treatment
change from the Epworth sleepiness scale at one week
Lasso di tempo: one week
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The scale has an overall score range of 0 to 24, with higher scores indicating more severe sleepiness.
one week
change from Parkinson's disease sleep scale at one week
Lasso di tempo: one week
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 150. The higher the score, the better the sleep.
one week
change from movement disorders association - comprehensive rating scale of Parkinson's disease at one week
Lasso di tempo: one week
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranged from 0 to 260, and the higher the score, the more severe the symptoms were.
one week
change from Parkinson's disease quality of life scale one week
Lasso di tempo: one week
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 156, and the higher the score, the worse the quality of life.
one week
change from Hamilton depression scale at one week
Lasso di tempo: one week
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranged from 0 to 96, and the higher the score, the more severe the depression was.
one week
change from Hamilton anxiety scale at one week
Lasso di tempo: one week
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 56, and the higher the score, the more serious the anxiety.
one week
change from simple mental state scale at one week
Lasso di tempo: one week
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 30, and the lower the score, the more severe the cognitive impairment.
one week
change from Montreal cognitive assessment scale at one week
Lasso di tempo: one week
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 30, and the lower the score, the more severe the cognitive impairment.
one week
change from magnetic resonance imaging of the brain at one month
Lasso di tempo: one month
The ADC values of sleep-related brain tissues were measured by diffusion weighted magnetic resonance imaging of the brain.Compare the difference between the measured results on both sides of the same site and record the difference.
one month

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Xiuhua Li, MD, Qianfoshan Hospital,The First Affiliated Hospital of Shandong First Medical University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 dicembre 2019

Completamento primario (Anticipato)

20 dicembre 2021

Completamento dello studio (Anticipato)

20 aprile 2022

Date di iscrizione allo studio

Primo inviato

8 marzo 2021

Primo inviato che soddisfa i criteri di controllo qualità

15 marzo 2021

Primo Inserito (Effettivo)

18 marzo 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 marzo 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 marzo 2021

Ultimo verificato

1 marzo 2021

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Morbo di Parkinson

3
Sottoscrivi